Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) fell 2.5% during mid-day trading on Wednesday. The stock traded as low as C$0.38 and last traded at C$0.39. Approximately 82,525 shares changed hands during trading, a decline of 5% from the average daily volume of 87,218 shares. The stock had previously closed at C$0.40.
Medicenna Therapeutics Stock Down 2.5%
The business’s 50 day simple moving average is C$0.41 and its 200 day simple moving average is C$0.48. The company has a market capitalization of C$35.54 million, a PE ratio of -1.75 and a beta of 3.00. The company has a quick ratio of 4.65, a current ratio of 1.25 and a debt-to-equity ratio of 6.22.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
See Also
- Five stocks we like better than Medicenna Therapeutics
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
